238 related articles for article (PubMed ID: 33619776)
1. Addressing challenges associated with long-term topical treatment and benefits of proactive management in patients with psoriasis.
Lebwohl M; Thaçi D; Warren RB
J Eur Acad Dermatol Venereol; 2021 Feb; 35 Suppl 1(Suppl 1):35-41. PubMed ID: 33619776
[TBL] [Abstract][Full Text] [Related]
2. Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial).
Lebwohl M; Kircik L; Lacour JP; Liljedahl M; Lynde C; Mørch MH; Papp KA; Perrot JL; Gold LS; Takhar A; Thaçi D; Warren RB; Wollenberg A
J Am Acad Dermatol; 2021 May; 84(5):1269-1277. PubMed ID: 32950546
[TBL] [Abstract][Full Text] [Related]
3. PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis.
Stein Gold L; Alonso-Llamazares J; Lacour JP; Warren RB; Tyring SK; Kircik L; Yamauchi P; Lebwohl M;
Adv Ther; 2020 Nov; 37(11):4730-4753. PubMed ID: 32965655
[TBL] [Abstract][Full Text] [Related]
4. Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal/BD foam: A post-hoc analysis of PSO-LONG.
Jalili A; Calzavara-Pinton P; Kircik L; Lons-Danic D; Pink A; Tyring S; de la Cueva P; Gooderham M; Segaert S; Nyholm N; Thoning H; Petersen B; Thaçi D
J Eur Acad Dermatol Venereol; 2022 Jan; 36(1):60-67. PubMed ID: 34543474
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of proactive treatment with twice-weekly topical Cal/BD foam in patients with plaque psoriasis undergoing HPA-axis testing: a PSO-LONG subgroup analysis.
Papp K; Adamski Z; Guenther L; Liljedahl M; Miasik-Pogodzinska A; Szponar-Bojda A; Lynde C; Nutt T; Mørch MH; Tyring S; Werschler W; Reich A; Sadick N; Turchin I; Lacour JP
J Dermatolog Treat; 2022 Jun; 33(4):2297-2304. PubMed ID: 34365872
[TBL] [Abstract][Full Text] [Related]
6. Clinical, patient and estimated cost benefits of proactive management versus reactive management with calcipotriol/betamethasone dipropionate foam for the treatment of plaque psoriasis in Finland.
Harvima RJ; Gooderham M; Tyring S; Thoning H; Nyholm N; Stein Gold L
J Dermatolog Treat; 2022 Jun; 33(4):2234-2240. PubMed ID: 34130573
[TBL] [Abstract][Full Text] [Related]
7. Long-term proactive management of psoriasis with calcipotriol and betamethasone dipropionate foam: an Italian consensus through a combined nominal group technique and Delphi approach.
De Simone C; Dapavo P; Malagoli P; Martella A; Campanati A; Campione E; Errichetti E; Franchi C; Gambardella A; Megna M; Osti F; Ribero S; Zagni G; Calzavara-Pinton P; Fabbrocini G; ; Amoruso GF; Baglieri F; Biamonte AS; Bianchelli T; Bigi L; Bortoli J; Brunetti B; Buligan C; Cagni E; Calderoni O; Calzavara-Pinton P; Campanati A; Caputo A; Carrera CG; Carugno A; Chersi K; Cicchelli S; De Natale F; De Simone C; Dapavo P; Di Maria D; Errichetti E; Fabbrocini G; Ferrari AS; Fogli E; Forconi R; Franchi C; Galeazzi A; Gambardella A; Giovannini A; Giura MT; Iuculano M; Lazzaretti G; Leporati C; Magnanini M; Malagoli P; Marconi B; Martella A; Maruccia A; Megna M; Miglietta R; Minuti A; Mocci L; Modica S; Narcisi A; Odorici G; Osti F; Pazzaglia M; Peila R; Pertusi G; Pezza M; Pezzullo E; Puccia N; Raulo U; Ribero S; Rossi M; Rusignuolo S; Sapienza G; Savarese C; Scalisi M; Strippoli D; Stroppiana E; Tiberio R; Trischitta A; Tucci MG; Vaira F; Verrone A; Villa L; Zagni F; Zoccali A
Int J Dermatol; 2022 Dec; 61(12):1543-1551. PubMed ID: 35609147
[TBL] [Abstract][Full Text] [Related]
8. Expert Consensus on Real-World Use and Consumption Patterns of a Fixed-Dose Combination Foam for Psoriasis as a Reactive Management (RM) and Proactive Management (PAM) Regimen.
Perry R; Beveridge AJ; Sears AJ; Rasmussen ER
Adv Ther; 2023 Mar; 40(3):1062-1073. PubMed ID: 36627543
[TBL] [Abstract][Full Text] [Related]
9. The Effect on BSA of Proactive Management versus Reactive Management of Psoriasis With Fixed-Dose Cal/BD Foam in the PSO-LONG Study.
Takhar A; Thoning H; Nyholm N; Petersen B; Stein Gold L
J Drugs Dermatol; 2021 May; 20(5):567-570. PubMed ID: 33938704
[TBL] [Abstract][Full Text] [Related]
10. Calcipotriol/betamethasone foam for proactive management of plaque psoriasis: four case reports.
Apalla Z; Perrussel M; Rallis E
Drugs Context; 2022; 11():. PubMed ID: 35864998
[TBL] [Abstract][Full Text] [Related]
11. Calcipotriol/betamethasone dipropionate aerosol foam in the treatment of psoriasis: new perspectives for the use of an innovative topical treatment from real-life experience.
Fabbrocini G; Dauden E; Jalili A; Bewley A
G Ital Dermatol Venereol; 2020 Apr; 155(2):212-219. PubMed ID: 32394674
[TBL] [Abstract][Full Text] [Related]
12. Impact of fixed-dose combination Cal/BD foam on the work productivity of patients with psoriasis: results from the 52-week randomized, double-blind, PSO-LONG trial.
Guenther L; Takhar A; Megna M; Sebastian M; Nyholm N; Thoning H; Levin LÅ
J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):1054-1063. PubMed ID: 35297108
[TBL] [Abstract][Full Text] [Related]
13. Long-term maintenance treatment of psoriasis: the role of calcipotriol/betamethasone dipropionate aerosol foam in clinical practice.
Fabbrocini G; De Simone C; Dapavo P; Malagoli P; Martella A; Calzavara-Pinton P
J Dermatolog Treat; 2022 Aug; 33(5):2425-2432. PubMed ID: 34694953
[TBL] [Abstract][Full Text] [Related]
14. Calcipotriol/betamethasone dipropionate foam demonstrates comparable efficacy to clinical trial data in the real world, improves patient satisfaction and is cost-effective.
Armstrong A; Gerdes S
J Eur Acad Dermatol Venereol; 2021 Feb; 35 Suppl 1():28-34. PubMed ID: 33619780
[TBL] [Abstract][Full Text] [Related]
15. Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study.
Griffiths CE; Stein Gold L; Cambazard F; Kalb RE; Lowson D; Møller A; Paul C
Eur J Dermatol; 2018 Jun; 28(3):356-363. PubMed ID: 29952297
[TBL] [Abstract][Full Text] [Related]
16. Fixed combination calcipotriol plus betamethasone dipropionate aerosol foam in the treatment of psoriasis vulgaris: rationale for development and clinical profile.
Paul C; Bang B; Lebwohl M
Expert Opin Pharmacother; 2017 Jan; 18(1):115-121. PubMed ID: 27936972
[TBL] [Abstract][Full Text] [Related]
17. Proactive vs. reactive psoriasis therapy: a long-term evaluation with dermoscopic and confocal microscopy assessment.
Cacciapuoti S; Ruggiero A; Gallo L; Fabbrocini G
Eur Rev Med Pharmacol Sci; 2022 Mar; 26(6):2018-2024. PubMed ID: 35363352
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).
Leonardi C; Bagel J; Yamauchi P; Pariser D; Xu Z; Olesen M; Østerdal ML; Stein Gold L
J Drugs Dermatol; 2015 Dec; 14(12):1468-77. PubMed ID: 26659941
[TBL] [Abstract][Full Text] [Related]
19. Fixed-dose combination calcipotriol/betamethasone dipropionate foam provides a rapid onset of action, effective itch relief and improves patient quality of life.
Jalili A; Yosipovitch G
J Eur Acad Dermatol Venereol; 2021 Feb; 35 Suppl 1(Suppl 1):20-27. PubMed ID: 33619778
[TBL] [Abstract][Full Text] [Related]
20. Rapid onset of action of calcipotriol/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease.
Pink AE; Jalili A; Berg P; Calzavara-Pinton PG; de la Cueva Dobao P; Thaçi D; Torpet M; Jensen KL; Segaert S
J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1116-1123. PubMed ID: 30916417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
